A detailed history of Qube Research & Technologies LTD transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 165,190 shares of SAGE stock, worth $946,538. This represents 0.0% of its overall portfolio holdings.

Number of Shares
165,190
Previous 234,021 29.41%
Holding current value
$946,538
Previous $2.54 Million 53.13%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.02 - $13.08 $483,193 - $900,309
-68,831 Reduced 29.41%
165,190 $1.19 Million
Q2 2024

Aug 14, 2024

BUY
$10.58 - $17.9 $1.35 Million - $2.29 Million
127,903 Added 120.53%
234,021 $2.54 Million
Q1 2024

May 14, 2024

BUY
$18.62 - $26.95 $1.09 Million - $1.58 Million
58,694 Added 123.76%
106,118 $1.99 Million
Q4 2023

Feb 13, 2024

BUY
$17.1 - $22.26 $810,950 - $1.06 Million
47,424 New
47,424 $1.03 Million
Q2 2023

Aug 14, 2023

BUY
$40.65 - $59.54 $3.17 Million - $4.64 Million
77,924 New
77,924 $3.66 Million
Q4 2022

Feb 14, 2023

BUY
$32.2 - $43.61 $256,086 - $346,830
7,953 New
7,953 $303,000
Q4 2021

Feb 01, 2022

SELL
$37.06 - $47.11 $1.06 Million - $1.35 Million
-28,697 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$40.26 - $57.37 $572,014 - $815,112
14,208 Added 98.06%
28,697 $1.27 Million
Q2 2021

Aug 13, 2021

SELL
$54.88 - $79.29 $2.71 Million - $3.92 Million
-49,418 Reduced 77.33%
14,489 $823,000
Q1 2021

May 14, 2021

BUY
$70.65 - $96.76 $3.42 Million - $4.69 Million
48,432 Added 312.97%
63,907 $4.78 Million
Q4 2020

Feb 16, 2021

BUY
$58.41 - $89.06 $903,894 - $1.38 Million
15,475 New
15,475 $1.34 Million
Q2 2020

Aug 14, 2020

SELL
$25.95 - $43.15 $693,851 - $1.15 Million
-26,738 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$26.15 - $77.24 $699,198 - $2.07 Million
26,738 New
26,738 $768,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $340M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.